Riskpilot← Back to searchSign inGet full accessLabmed Oy
OYDissolvedY-tunnus 1995905-1Temppelikatu 17-B42Medical specialists activities · NACE 8622Est. 20050 employees
Revenue 2025
EUR 215K
-14% vs 2024
EBITDA margin
44.7%
0% vs 2024
Equity ratio
99.9%
Financial strength
Net profit 2025
EUR 75K
-99% vs 2024
| Revenue | EUR 215K | -14% |
| EBITDA | EUR 96K | +0% |
| Net profit | EUR 75K | -99% |
| Total assets | EUR 277K | +8% |
| Equity | EUR 277K | -99% |
| Employees | 0 | — |
Legal name
Labmed Oy
Y-tunnus number
1995905-1
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
25. lokakuuta 2005
Share capital
EUR 8 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on lääkäripalvelujen tarjoaminen ja konsultointi mukaan lukien lääketieteellinen diagnostiikka sekä lääketieteellinen neuvonta-, tutkimus-, tuotekehittely-, keksintö-, patentointi-, koulutus-, kongressi-, julkaisu- ja kustannustoiminta. Yhtiö voi tuoda maahan, myydä ja edustaa lääketieteellisiä laitteita, lääkkeitä, kulutustavaroita ja palveluja. Yhtiö voi hallita ja vuokrata kiinteistöjä ja arvopapereita sekä käydä niillä kauppaa.
Address
Temppelikatu 17-B42
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 238 | 265 | 485 | 251 | 215 |
| Staff expenses | −86 | −37 | −30 | −78 | −49 |
| EBITDA | 47 | 85 | 137 | 97 | 96 |
| Depreciation & amort. | −0 | −0 | — | −0 | −2 |
| EBIT | 47 | 85 | 137 | 9 662 | 94 |
| Net financials | −0 | −1 | 0 | −0 | 0 |
| Profit before tax | 47 | 85 | 137 | 97 | 94 |
| Tax | 20 | 14 | 24 | 20 | 19 |
| Net profit | 27 | 71 | 113 | 7 688 | 75 |
| Item | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 73 | 114 | 213 | 255 | 277 |
| Equity | 70 | 112 | 194 | 25 131 | 277 |
| Long-term debt | — | — | — | 0 | 0 |
| Short-term debt | 3 | 3 | 19 | 406 | 0 |
| Total debt | 3 | 3 | 19 | 406 | 0 |
EBITDA margin
44.7%
This company
15.8%
Market median
+183% vs market
20202025
Equity ratio
99.9%
This company
38.2%
Market median
+162% vs market
20202025
Return on equity
27.2%
This company
18.4%
Market median
+48% vs market
20202025
Net profit margin
35.0%
This company
8.1%
Market median
+332% vs market
20202025
Asset turnover
0.78×
This company
1.12×
Market median
-30% vs market
20202025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202025
- Annual report 2025Filed via PRH / YTJ · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via PRH / YTJ · Period 2023-04-01 – 2024-03-31
- Annual report 2022Filed via PRH / YTJ · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via PRH / YTJ · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via PRH / YTJ · Period 2019-04-01 – 2020-03-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
TM Audit | Audit | 2021 |
JI Deputy Member | Deputy Member | 2006 |
PJ Deputy auditor | Deputy auditor | 2021 |
| Former (1) | ||
TH Audit | Audit | 2017 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2006 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Labmed Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Timo Matti Kervinen | Audit | 0 companies |
| Teija Helena Moisala | Audit | 0 companies |
| Juha-Pekka Ilmari Vasama | Deputy Member | 0 companies |
| Perttu Johannes Mettomäki | Deputy auditor | 0 companies |
| Petri Severi Mattila | Board of Directors | 0 companies |